Hympavzi now approved for more hemophilia patients in Europe
WHY IT MATTERS
European hemophilia patients with inhibitors now have access to Hympavzi, a subcutaneous therapy that may reduce bleeding episodes and improve quality of life compared to traditional intravenous treatments.
Hympavzi, a new hemophilia treatment made by Pfizer, has been approved in Europe for more patients. The drug helps people with hemophilia A or B who have developed inhibitors—a complication where the body fights back against standard treatments. This approval expands who can use the medicine to help them bleed less and stay healthier.
The European Commission has approved Hympavzi (marstacimab) to treat certain people with hemophilia A or hemophilia B who have inhibitors, the therapy’s maker, Pfizer, announced. Hympavzi was approved in Europe in 2024 to treat patients with hemophilia A or B ages 12 and older who weigh at least 35 kg (77 pounds) and do not […] The post Hympavzi now approved for more hemophilia patients in Europe appeared first on Hemophilia News Today .
YOU CAN ACT ON THIS
If you have hemophilia A or B with inhibitors in Europe, ask your hematologist immediately whether Hympavzi is appropriate for you and how to access it through your healthcare system.